We are live on ! Find out more
PASG icon

Passage Bio
PASG

43 hedge funds and large institutions have $32M invested in Passage Bio in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

0.36% less ownership

Funds ownership: 3.62% → 3.27% (-0.36%)

10% less funds holding

Funds holding: 48 → 43 (-5)

36% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 11

41% less capital invested

Capital invested by funds: $54.4M → $32M (-$22.4M)

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

Holders
43
Holders Change
-5
Holders Change %
-10.42%
% of All Funds
0.62%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
4
Increased
7
Reduced
11
Closed
9
Calls
$7K
Puts
–
Net Calls
+$7K
Net Calls Change
-$40K

Top Buyers

1
VPC
Vestal Point Capital
New York
+$1.9M
2
LCM
Lynx1 Capital Management
Puerto Rico
+$259K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$57.3K
4
TRCT
Tower Research Capital (TRC)
New York
+$16.1K
5
AI
Acuitas Investments
Washington
+$3.08K

Top Sellers

1
VVM
Versant Venture Management
California
-$1.14M
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$283K
3
PFCS
Pale Fire Capital SE
Czech Republic
-$191K
4
Millennium Management
Millennium Management
New York
-$140K
5
BlackRock
BlackRock
New York
-$128K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$8.04M – – –
VPC
2
Vestal Point Capital
New York
$4.81M +$1.9M +77,600 +34%
LCM
3
Lynx1 Capital Management
Puerto Rico
$4.02M +$259K +10,587 +4%
VVM
4
Versant Venture Management
California
$3.2M -$1.14M -46,667 -19%
NLVP
5
New Leaf Venture Partners
New York
$1.98M – – –
EAM
6
Erste Asset Management
Austria
$1.96M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$1.65M – – –
TCM
8
Tang Capital Management
California
$1.19M – – –
Renaissance Technologies
9
Renaissance Technologies
New York
$894K -$97.8K -3,997 -7%
Acadian Asset Management
10
Acadian Asset Management
Massachusetts
$762K – – –
BlackRock
11
BlackRock
New York
$649K -$128K -5,251 -11%
Millennium Management
12
Millennium Management
New York
$596K -$140K -5,741 -13%
BCM
13
Bridgeway Capital Management
Texas
$442K – – –
AI
14
Acuitas Investments
Washington
$375K +$3.08K +126 +0.5%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$342K +$57.3K +2,342 +12%
AAA
16
Affinity Asset Advisors
New York
$210K – – –
FT
17
Fiduciary Trust
Massachusetts
$171K – – –
Citadel Advisors
18
Citadel Advisors
Florida
$126K -$77.4K -3,165 -29%
RC
19
RBF Capital
California
$113K – – –
State Street
20
State Street
Massachusetts
$98.4K – – –
Two Sigma Investments
21
Two Sigma Investments
New York
$82.5K -$119K -4,865 -48%
MAM
22
Marquette Asset Management
Minnesota
$67.9K – – –
Northern Trust
23
Northern Trust
Illinois
$51.2K -$24.2K -987 -23%
DIM
24
DLK Investment Management
California
$50.8K – – –
Goldman Sachs
25
Goldman Sachs
New York
$21.6K +$343 +14 +1%
1
2 3

PASG Hedge Fund Activity: Q2 2024 in Review

43 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q2 2024, worth a combined $32M — down 41% from $54.4M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of PASG and 4 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 7 added.

The largest buyer was Vestal Point Capital, adding an estimated $1.9M. The largest seller was Versant Venture Management, cutting an estimated $1.14M.

  • 43 institutional investors held Passage Bio (PASG) as of Q2 2024, down from 48 in Q1 2024.
  • Funds reported $32M of Passage Bio stock for Q2 2024, down 41% quarter-over-quarter.
  • 4 funds opened new Passage Bio positions in Q2 2024 and 9 closed out, a net change of -5 holders.
  • The largest Passage Bio buyer in Q2 2024 was Vestal Point Capital, an estimated $1.9M added.
  • The largest Passage Bio seller in Q2 2024 was Versant Venture Management, an estimated $1.14M sold.

Based on aggregated 13F filings for Q2 2024.